A survey of the U.S. population in 2014 witnessed that Americans consume approximately 31% more packaged food than fresh food and the healthiness of the food reduce by 1.7% at every hour that passes. Secondary hyperoxaluria is a medical condition in the body that absorbs large concentration of oxalate directly through food. Chocolate, Beans, Beer, and coffee among other are some of the products that are high in oxalate concentration. Thus, the lack in dietary awareness is the major reason of secondary hyperoxaluria which is anticipated to boost the market growth.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-secondary-hyperoxaluria-drug-market
Data Bridge Market Research analyses that the secondary hyperoxaluria drug market is expected to reach USD 38,386.55 million by 2030 from USD 610.72 million in 2022, growing with the healthy CAGR of 67.80% in the forecast period of 2023 to 2030. Increasing funding activities by some health organizations or by offering share will provide financial support in research and will provide potential opportunities for the market growth in the forecast period.
Targeted treatment for secondary hyperoxaluria is in high demand, which is expected to drive the market's growth rate
Secondary hyperoxaluria is an illness that is caused by the precursor of oxalate whose end product is oxalate or by the excessive dietary intake of oxalate, or by the micro-environmental changes in gut flora. There are several therapies which are associated with the prophylaxis and treatment of secondary hyperoxaluria but these are not targeted to treat this disease such as thiazide diuretics and other supplement. These all can be measured as secondary treatments for this disease. As there is no main treatment option available for secondary hyperoxaluria in the market the health care providers and patient are dependent on nutritional and supplementary treatment. The demand for the treatment rise after knowing the adverse complication associated with this disease such as calcium oxalate stone.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Reloxaliase, Thiazide Diuretics and Supplements), Drug Type (Prescription and Over the Counter), Population Type (Children and Adults), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Nestlé (Switzerland), GlaxoSmithKline plc (U.K.), Bayer AG (Germany), Pharmavite (U.S.), Solgar Inc. (U.S.), Mission Pharmacal Company (U.S.), Oystershell, (Belgium), Allena Pharmaceuticals, Inc. (U.S.), Celebrate Vitamins (U.S.),, OxThera (Sweden), Renew Life Formulas, Inc. (U.S.), Synlogic (U.S.), TIENS (China), Amway Corp.,(U.S.) Infinitus (China), Now Foods (U.S.), Nature's Bounty (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The secondary hyperoxaluria drug market is segmented on the basis of type, drug type, population type, end user and distribution channel.
- On the basis of type, the global secondary hyperoxaluria drug market is segmented into reloxaliase, thiazide diuretics and supplements.
In 2022, the supplements segment of type segment is anticipated to dominate the secondary hyperoxaluria drug market
Supplements segment is expected to dominate the market and is expected to reach USD 779.77 million by 2030 in the forecast period of 2023 to 2030 because there is no availability of targeted therapy. However, some products are in the clinical trials and are anticipated to enter interstate commerce in the upcoming period. So, the management of the diseases is done by dietary restrictions and supplements. Magnesium supplements, Calcium supplements, and other supplements help as main line of treatment along with probiotics, fluid intake and dietary restrictions which are used to maintain the gut flora.
- On the basis of drug type, the global secondary hyperoxaluria drug market is segmented into prescription and over the counter. In 2022, the over-the-counter segment is expected to dominate the market and reach USD 940.47 million by 2030 in the forecast period of 2023 to 2030 because over-the-counter drugs are available without prescription and are easily accessible as supplements. Thus, physicians recommend this drugs and suggest it should be consumed with regular diet.
- On the basis of population type, the global secondary hyperoxaluria drug market is segmented into children and adults. In 2022, adults segment is expected to dominate the market and is expected to reach USD 39,997.91 million by 2030 in the forecast period of 2023 to 2030 because the diagnosis for secondary hyperoxaluria in adults is generally carried out for high oxalate excretion in the urine along with UTI and indications of kidney stone. The prevalence of kidney stones is not common in children and the number of cases for this disease is relatively very low as compared to adults.
- On the basis of end user, the global secondary hyperoxaluria drug market into hospitals, specialty clinics, home healthcare and others. In 2022, home healthcare segment is expected to dominate the market and is expected to reach USD 25,644.26 million by 2030 in the forecast period of 2023 to 2030 due to the fact that the current treatment includes thiazide diuretics and supplements. Patients take these products at home without the help of any supervision and medical professional.
- On the basis of distribution channel, the global secondary hyperoxaluria drug market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others.
In 2022, the retail pharmacies segment of distribution channel segment is anticipated to dominate the secondary hyperoxaluria drug market
Retail pharmacies segment is expected to dominate the market and is expected to reach USD 27,852.64 million by 2030 in the forecast period of 2023 to 2030 because the numbers of retail pharmacies are very high and growing with year passing. They deal with large number of patients for purchasing drugs in traditional consumer purchase style. Furthermore, retail pharmacies are focusing on expanding their services for better customer service.
Major Players
Data Bridge Market Research recognizes the following companies as the major secondary hyperoxaluria drug market players in secondary hyperoxaluria drug market Nestlé (Switzerland), GlaxoSmithKline plc (U.K.), Bayer AG (Germany), Pharmavite (U.S.), Solgar Inc. (U.S.), Mission Pharmacal Company (U.S.), Oystershell, (Belgium), Allena Pharmaceuticals, Inc. (U.S.), Celebrate Vitamins (U.S.), OxThera (Sweden).
Market Development
- In June 2020, Nestle Health Science focused on nutrition science and decided to develop the market by acquiring majority stakes in Vital Proteins, which provide food products, beverages, and supplements. This acquisition is subjected to regulatory approval challenges and is a great opportunity for Nestle Health Science to create a way to expand more in nutrition business.
Regional Analysis
Geographically, the countries covered in the secondary hyperoxaluria drug market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
As per Data Bridge Market Research analysis:
North America is the dominant region in secondary hyperoxaluria drug market during the forecast period 2023 to 2030
North America dominates the secondary hyperoxaluria drug market due to growing demand for secondary hyperoxaluria drug in Canada and United States. The high expense of healthcare, high disposable income of general population, and the presence of major market players of secondary hyperoxaluria drug treatment are some of the other factors that will be projected to promote revenue growth.
Asia-Pacific is estimated to be the fastest-growing region in secondary hyperoxaluria drug market the forecast period 2023 to 2030
Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 owing to changing lifestyles and increasing urbanization in supplements segment. China is anticipated to dominate in the Asia-Pacific secondary hyperoxaluria drug market because China is one of the leading nation in the world with rapidly growing product usage and diagnosis rate with increasing awareness regarding secondary hyperoxaluria.
For more detailed information about secondary hyperoxaluria drug market report, click here – https://www.databridgemarketresearch.com/reports/global-secondary-hyperoxaluria-drug-market
